
This study evaluates long-term outcomes after septal reduction therapy (SRT) in patients with obstructive hypertrophic cardiomyopathy (HCM) using data from the SHARE registry. Among 1,832 patients who underwent SRT, the 30-day mortality rate was low at 0.4%. Over a median follow-up of 6.8 years, the incidence of HCM-related death was 4%, and 13% experienced heart failure (HF) composite outcomes. Older age, female sex, and SRT in childhood were significant predictors of adverse outcomes, with 83% of patients remaining event-free at 10 years.
Like
Save
Share